Blood testing market size worth $140.3 billion by 2028

The global blood testing market size is expected to reach USD 140.3 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.3% from 2021 to 2028. The shortened length of stay at hospitals and reduced contact between patient and concerned physician coupled with the rise in outpatient services have increased the demand for blood testing services. Additionally, the growing prevalence of target diseases such as diabetes, COVID-19, and cardiovascular diseases is expected to drive the market at a significant rate.

The preliminary blood testing techniques employed in medical and wellness settings play a crucial role in the management of patient health and prevention of cardiovascular disorders along with diabetes. However, presently several novel blood tests have been introduced into the market, which detect circulating DNA fragments in the bloodstream to facilitate diagnosis. Such tests, including, cancer and prenatal tests; have gained immediate traction as they are comparatively sophisticated. Thus, expanding research activities to unlock the potential of blood tests is expected to boost the market growth.

On the other hand, several biotech companies are investing in the development of cutting-edge, affordable blood testing products that could be employed each time at a doctor’s visit. For instance, SomaLogic, a company operational in Colorado, has developed the SOMAscan platform. This platform functions by quantifying large amounts of proteins in a blood sample to find relevant health traits in susceptible individuals. The company has already employed this approach to develop tests that detect early signs of heart disorders, liver disease, and diabetes, among few other conditions.

Scientists at Washington University in St. Louis (WUSTL) have recently performed a research activity showcasing a relatively faster and simpler blood testing solution. This blood test is designed to detect Covid-19 patients with higher susceptibility to severe complications or fatality in one day of hospital admission. This product detects mitochondrial DNA levels indicating predictable cell death in the body. Grand View Research